Skip to main content

Coherus BioSciences Mourns the Passing of Board Member Dr. Samuel Nussbaum

Written by Customer Service on . Posted in Public Companies.

REDWOOD CITY, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) — It is with profound sadness that Coherus BioSciences, Inc. (Nasdaq: CHRS) announces the passing of board member Samuel Nussbaum, M.D. During his distinguished career, Dr. Nussbaum worked as a physician, researcher, professor, and healthcare executive. He had been a director of the Company since May 2018.

“We will greatly miss Sam and his tremendous support for Coherus. Long before joining the Coherus board, he lived a mission of providing greater access to life-changing medicines,” said Denny Lanfear, CEO of Coherus. “We were privileged to benefit from his guidance and counsel during his time on our Board, and I will forever be grateful for his service. The entire Coherus team offers our condolences to the Nussbaum family at this time.”

From 2000 to 2016, Dr. Nussbaum served as Executive Vice President, Clinical Health Policy, and Chief Medical Officer for Anthem. Since retiring from Anthem, Dr. Nussbaum served as a strategic advisor to life science companies, health care systems and provider organizations, and life science investors.

Dr. Nussbaum’s long and varied career began with two decades at Harvard Medical School and Massachusetts General Hospital where he led the Clinical Endocrine Group Practice. He earned his B.A. from New York University and his M.D. from Mount Sinai School of Medicine. He trained in internal medicine at Stanford University and Massachusetts General Hospital and in endocrinology at Harvard Medical School and Massachusetts General Hospital.

About Coherus BioSciences
Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients’ lives and to deliver significant savings to the health care system. For additional information, please visit www.coherus.com.

Coherus Contact Information:
Cheston Turbyfill
Vice President, Communications
IR@coherus.com

 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.